Kimberlee C. Drapkin

Kimberlee C. Drapkin is recorded as CEO, Chief Accounting Officer and CFO at LENZ Therapeutics, Inc. (LENZ) since August 21, 2023 and Board Member at LENZ Therapeutics, Inc. (LENZ) since January 1, 2023. The newest filing on record that lists Kimberlee C. Drapkin as Board Member at LENZ Therapeutics, Inc. (LENZ) is dated April 28, 2026. LENZ Therapeutics, Inc. reported in an 8-K filed March 22, 2024 that Kimberlee C. Drapkin was appointed Class III director, effective March 21, 2024. LENZ Therapeutics, Inc. reported in an 8-K filed August 23, 2023 that Kimberlee C. Drapkin was appointed principal executive, financial and accounting officer, effective August 21, 2023. LENZ Therapeutics, Inc. reported in an 8-K filed August 23, 2023 that Kimberlee C. Drapkin was appointed President and Chief Executive Officer, effective August 21, 2023. Equibles holds 4 filed executive changes naming Kimberlee C. Drapkin; each is listed under recent activity with its source filing. The proxy statement of LENZ Therapeutics, Inc. reports total compensation of $1,097,345 for Kimberlee C. Drapkin in fiscal 2024, including a base salary of $163,541. Disclosed compensation is on record for 2 fiscal years. LENZ Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at LENZ Therapeutics, Inc. includes Daniel Chevallard (CEO and CFO), Jeff George (Chairman and Board Member), Mr. George (Chairman) and 6 others.